Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors
Authors:
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 125 (8) , 1279-1286
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- META-ANALYSIS OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTSRetina, 2011
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMABRetina, 2008
- Acute Intraocular Inflammation after Intravitreous Injections of Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2008
- Effect of lidocaine gel on povidone–iodine antisepsis and microbial survivalJournal of Cataract & Refractive Surgery, 2008
- Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Injections in An Office SettingAmerican Journal of Ophthalmology, 2008
- INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTIONRetina, 2008
- Acute-Onset Endophthalmitis after Clear Corneal Cataract Surgery (1996–2005)Ophthalmology, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006